TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01576510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Description: Prolonged Exposure (PE) therapy consists of ten 90-minute sessions. Elements of PE include imaginal and in vivo exposure to trauma reminders; breathing retraining; cognitive restructuring; and PTSD psychoeducation. The therapist helps the patient cognitively restructure his/her experience of the traumatic event. Each week the narrative is elaborated, becoming more detailed and exhaustive, until the patient habituates to it, extinguishing the anxiety it formerly aroused.
Study: NCT02373813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept pre-filled syringe subcutaneous injection
Description: etanercept for injection in pre-filled syringes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept pre-filled syringe subcutaneous injection
Description: etanercept for injection in pre-filled syringes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept pre-filled syringe subcutaneous injection
Description: etanercept for injection in pre-filled syringes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept pre-filled syringe subcutaneous injection
Description: etanercept for injection in pre-filled syringes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral methotrexate
Description: During the open-label run-in period, methotrexate will be provided as 2.5 mg tablets.~During the double-blind treatment period, methotrexate will be provided as 2.5 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral methotrexate
Description: During the open-label run-in period, methotrexate will be provided as 2.5 mg tablets.~During the double-blind treatment period, methotrexate will be provided as 2.5 mg capsules.
Study: NCT03816579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRO-B
Description: 30 g of complementary proteins will be consumed at each meal
Study: NCT02373813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral methotrexate
Description: During the open-label run-in period, methotrexate will be provided as 2.5 mg tablets.~During the double-blind treatment period, methotrexate will be provided as 2.5 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral methotrexate
Description: During the open-label run-in period, methotrexate will be provided as 2.5 mg tablets.~During the double-blind treatment period, methotrexate will be provided as 2.5 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for etanercept subcutaneous injection
Description: etanercept placebo for injection in pre-filled syringes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for methotrexate
Description: methotrexate placebo capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid (non-investigational product)
Description: Folic acid 5 to 7 mg per week as per investigator judgment or according to local standard of care.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid (non-investigational product)
Description: Folic acid 5 to 7 mg per week as per investigator judgment or according to local standard of care.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid (non-investigational product)
Description: Folic acid 5 to 7 mg per week as per investigator judgment or according to local standard of care.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid (non-investigational product)
Description: Folic acid 5 to 7 mg per week as per investigator judgment or according to local standard of care.
Study: NCT03344289

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Participants will be randomized towards colonoscopy withdrawal with either LCI or HD-WLE

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Participants will be randomized towards colonoscopy withdrawal with either LCI or HD-WLE
Study: NCT03279198

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TIWeb
Description: Intervention: TIWeb program is interactive and tailored to the participant's individual beliefs and demographics. Individuals receiving the TIWeb will be given information that allows them to call and receive an FOBT kit in the mail or schedule an appropriate CRC test and/or mammogram.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CSC
Description: Intervention: CSC - a telephone counseling call during which the participant is given the opportunity to complete CRC screening (FOBT or a colonoscopy) and/or mammography screening.The CSC included tailored counseling as well as the ability to schedule BC and CRC screening tests.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: UC
Description: Intervention: The usual care group received usual care that varies dependent upon the practice setting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TIWeb+CSC
Description: Intervention: TIWeb + CSC ((Tailored web intervetion+Cancer screening) group receive a mailed TIWeb, which is followed in four weeks by a CSC with the same opportunity to receive FOBT kits or schedule a colonoscopy and/or mammogram. The nurse counselor, knowing the participant is a good candidate for screening tests, will be trained to schedule CRC or BC screening appointments or to mail FOBT kits to individuals in the intervention groups even if they have not had a recent clinic visit.
Study: NCT02547805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLN-177
Description: ALLN-177 7,500 units (5 capsules) PO TID with meals

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 5 capsules PO TID with meals
Study: NCT01746394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents as Teachers Enhanced
Description: Participants will receive the same monthly Parents as Teachers (PaT) lessons and materials at each home visit as the PaT arm. Additionally, these mothers will receive the enhanced nutrition and physical activity lessons and materials which will follow the family well-being format of the PaT lessons. The StartSmart lessons will focus on healthy gestational weight gain, diet, physical activity, breastfeeding, weight management, healthy eating, food shopping, meal preparation, physical activity, proper infant feeding, and infant activity time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parents as Teachers
Description: Participants will receive monthly Parents as Teachers (PaT) lessons and materials at each home visit. The Parent Educator will first connect with the mother by discussing or reviewing content from the prior visit; reflect on the mother's experience with continuing the parent-child activity from the prior visit; and agree on what will happen during the current visit. For the lesson plan, the Parent Educator will cover the following three areas using discussion, activities, and handouts: parent-child interaction, develop-centered parenting, and family well-being. In closing, the Parent Educator will review and evaluate the visit, talk about the mother's next step, and plan for the next visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents as Teachers
Description: Participants will receive monthly Parents as Teachers (PaT) lessons and materials at each home visit. The Parent Educator will first connect with the mother by discussing or reviewing content from the prior visit; reflect on the mother's experience with continuing the parent-child activity from the prior visit; and agree on what will happen during the current visit. For the lesson plan, the Parent Educator will cover the following three areas using discussion, activities, and handouts: parent-child interaction, develop-centered parenting, and family well-being. In closing, the Parent Educator will review and evaluate the visit, talk about the mother's next step, and plan for the next visit.
Study: NCT00788424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS101 Cream
Description: 4% AS101 Cream or Placebo cream, twice a day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS101 Cream
Description: 4% AS101 Cream or Placebo cream, twice a day for 12 weeks
Study: NCT03816579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRO-C
Description: 30 g of complementary proteins will be consumed over 24 hours
Study: NCT01933555

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowerment Program
Study: NCT04155632

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: N-acetylcysteine
Description: N-acetylcysteine (NAC) is a medication that is used to treat paracetamol (acetaminophen) overdose, and to loosen thick mucus in individuals with cystic fibrosis or chronic obstructive pulmonary disease. It has a long-established safety record in adults and children, with FDA approval since 1963. The side effects most commonly noted in people who take NAC by mouth include diarrhea, nausea, vomiting, and headache. These side effects are usually mild and go away even with continued use of NAC by mouth. There is also a risk of a skin reaction, such as flushing, itching, or rash. A meta-analysis of studies evaluating long-term oral treatment with NAC for prevention of chronic bronchitis found that NAC was well tolerated, with generally mild, most commonly gastrointestinal adverse effects that did not require treatment interruption.
Study: NCT01974921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALAIR Catheter. Radiofrequency system.
Description: Radiofrequency with Alair Catheter trhough flexible bronchoscopy in three different sessions (right lower lobe, left lower lobe, both upper lobes).
Study: NCT03831438

Intervention type: DRUG
Group type: OTHER
Intervention: AVID200
Description: Intravenous infusion of AVID200 Q2 weeks for 3 doses
Study: NCT06486935

Intervention type: DEVICE
Intervention: IoT sensors
Description: The proposed assistive Activities of Daily Living (ADL) monitoring system consists of ambient infrared sensors embedded seamlessly into the living environment, and a visualization app. Multimodality sensors with wireless data transmission capability will be installed at different locations (e.g. bedroom, kitchen, toilet, bathroom, living room, etc.) to monitor and detect the activities performed by individual elderly, such as cooking, sleeping, going to the bathroom, going out of the apartment or potential wandering, bathroom falls, etc. In addition, a micro-bend fiber optic pressure sensor mat will be placed unobtrusively below the bed mattress to measure the elderly's heart and respiratory rates during sleep. This mat helps provide information on the quality of sleep and sleep-wake rhythms of the elderly with sleep disorders. The collected data will then be transferred through a secured gateway with Raspberry Pi to a dedicated server for data processing and analysis.

Intervention type: OTHER
Intervention: Traditional/Manual elderly monitoring
Description: Traditional elderly care without the use of IoT sensors.
Study: NCT01608893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: 6.25 po bid titrated to 25 mg bid as tolerated over a 1 month period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: titrated to 50 mg po bid as tolerated over a 1 month period
Study: NCT02548793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education: CPR Training via Mobile App
Description: Using a mobile app to train users on chest-compression only CPR. Subjects will be encouraged to share the app with family and friends.
Study: NCT02460588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.~Intravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.
Study: NCT01222858

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Activity Education
Description: Education about behavioral modification of eating and activity habits for weight loss.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet and Activity Education
Description: Education about behavioral modification of eating and activity habits for weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring with Feedback
Description: Participants self-monitor diet and activity behaviors, which are submitted via a website. Automated feedback on the self-monitoring record is provided to participants.
Study: NCT00270829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesiritide
Description: Drug given intrarenally or placebo
Study: NCT02460588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid (prednisolone)
Description: All patients will receive non experimental medication with high dose of corticosteroid.
Study: NCT02288143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COOL-COS
Description: Controlled ovarian stimulation will start on the second or third day of a menstrual cycle:~* Oral clomiphene citrate: 100 mg/day until the day of the triggering.~* Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.~* hMG: 150 IU every other day beginning on the day 6 of the controlled ovarian stimulation.~The triggering will be performed using urinary hCG (5,000 IU subcutaneous).~* 1-2 days after the identification of one follicle ≥ 17 mm~* 0-1 days after the identification of one follicle ≥ 19 mm.
Study: NCT01133561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: actozone A
Description: pioglitazone 30 mg tablet , once daily dose for 10 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: actozone B
Description: one tablet of vehicle without active ingredient pioglitazone
Study: NCT00760214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil
Description: Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 40 mg, tablets, orally, once daily for up to 22 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil
Description: Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 80 mg, tablets, orally, once daily for up to 22 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Ramipril 2.5 mg, tablets, orally, once daily for two weeks; then increased to 10 mg, tablets, orally, once daily for up to 22 weeks.
Study: NCT02005432

Intervention type: DRUG
Group type: OTHER
Intervention: Intravitreal Ranibizumabe
Description: Intravitreal injection 0,05ml Ranibizumabe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Ranibizumabe
Description: Intravitreal injection 0,05ml Ranibizumabe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Ranibizumabe
Description: Intravitreal injection 0,05ml Ranibizumabe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panfotocoagulation (PASCAL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: panfotocoagulation (PRP) single shoot (ETDRS)
Study: NCT05254223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antiinflammatory Diet
Description: The intervention group is recommended to follow a diet, inspired in mediterranean diet, rich in anti-inflammatory foods. They are provided with a table with the recommended foods as well as the frequency of daily/weekly/biweekly consumption.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Diet
Description: The control group is recommended to follow their usual diet. Only in the case of detecting a serious nutritional problem the participant is recommended to correct it with the appropriate advice of the nutritionist.
Study: NCT04365257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: Participants in this arm will receive the study drug as outlined in the arm description.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Participants in this arm will receive standard of care.
Study: NCT02854176

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Somatosensory electrical stimulation

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Study: NCT02818231

Intervention type: OTHER
Intervention: Brushing of the olfactory cleft
Description: Non invasive sampling of olfactory cleft cells, by brushing under local anesthesia during fiberendoscopy Form: survey of acceptability

Intervention type: OTHER
Intervention: Brushing of the olfactory cleft
Description: Non invasive sampling of olfactory cleft cells, by brushing under local anesthesia during fiberendoscopy Form: survey of acceptability
Study: NCT00518973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of Quetiapine (or placebo) will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of placebo will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.
Study: NCT00430430

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High MUFA dietary portfolio
Description: high monounsaturated fat background diet to dietary portfolio

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low MUFA dietary portfolio
Description: low monounsaturated fat background diet to dietary portfolio
Study: NCT01454115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163 (Gamma-Secretase Inhibitor)
Description: Oral Solution, Oral, 0.3 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163 (Gamma-Secretase Inhibitor)
Description: Oral Solution, Oral, 1.5 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163 (Gamma-Secretase Inhibitor)
Description: Oral Solution, Oral, 5.0 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163 (Gamma-Secretase Inhibitor)
Description: Oral Solution, Oral, 15.0 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163 (Gamma-Secretase Inhibitor)
Description: Oral Solution, Oral, 50 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163 (Gamma-Secretase Inhibitor)
Description: Oral Solution, Oral, 50 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163 (Gamma-Secretase Inhibitor)
Description: Oral Solution, Oral, 50 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163 (Gamma-Secretase Inhibitor)
Description: Oral Solution, Oral, 100 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163 (Gamma-Secretase Inhibitor)
Description: Oral Solution, Oral, 200 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163 (Gamma-Secretase Inhibitor)
Description: Oral Solution, Oral, 400 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163 (Gamma-Secretase Inhibitor)
Description: Capsule, Oral, 50 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163 (Gamma-Secretase Inhibitor)
Description: Capsule, Oral, 50 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163 (Gamma-Secretase Inhibitor)
Description: Capsule, Oral, 50 mg, Once daily, once
Study: NCT02548793

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education: CPR Training using the CPR Anytime VSI Kit
Description: Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.